3 Red Flags for Inovio Pharmaceuticals' Future
In the early days of the coronavirus pandemic, Inovio Pharmaceuticals (NASDAQ: INO) was an exciting frontrunner in the vaccine race. The company garnered attention after it claimed to have created its candidate, DNA vaccine INO-4800, within three hours of receiving the genetic sequence of SARS-CoV-2 from a team of Chinese researchers. Fast-forward 10 months, and it's clear that Inovio significantly lags behind peers such as Moderna, Pfizer, and AstraZeneca, who already have phase 3 clinical trials underway.
Indeed, Inovio stock is now down nearly 70% from its peak as investors are arguably dismayed over the pace of Inovio's vaccine development. However, more concerning factors behind the company's rapid fall from grace still linger, and they point to a bleak future. Today let's take a look at why investors should be in no hurry to buy Inovio's stock on the dip.
Image source: Getty Images.
Source Fool.com